Novel strategy with acidic arginine solution for the treatment of influenza A virus infection (Review)

  • Authors:
    • Keiko Ikeda
    • Hisashi Yamasaki
    • Yukiko Suzuki
    • A. Hajime Koyama
    • Tsutomu Arakawa
  • View Affiliations

  • Published online on: March 1, 2010     https://doi.org/10.3892/etm_00000039
  • Pages: 251-256
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

There is already an indication of a potential worldwide spread of influenza projected for this coming autumn and winter. In this review, we propose an aqueous arginine solution as a novel agent for preventive measures and possible chemotherapy against influenza A virus infection. Influenza A virus spreads among the human population through both droplets and direct contact, and hand and mouth wash are the primary preventive measures. Upon contact, influenza A virus infects epithelial cells of the upper respiratory tracts in the initial phase of infection and spreads over the mucosal surface of the tracts, leading to varying degrees of inflammation near the site of infection. Arginine inactivates enveloped viruses, including influenza virus at an acidic pH or elevated temperature and hence may be used for preventive measures as a disinfectant and also for treatment of the infection. Because of the low cytotoxicity of arginine, virus inactivation may be performed at the site of infection in the form of a liquid or spray of an aqueous arginine solution. Acidic solvents have been used as a disinfectant and, to a limited extent, as a virus inactivation agent. Arginine may have the edge over acidic solvents due to its safety, or at least it may be used as an alternative option to acidic solvents or more specific antiviral drugs. Arginine as well as acidic solvents use a virus inactivation mechanism fundamentally different from the mechanism of antiviral chemotherapeutic drugs, i.e., through weak, but multiple, interactions with viral components. This eliminates the possibility of generating resistant viruses against arginine treatments.
View Figures
View References

Related Articles

Journal Cover

March-April 2010
Volume 1 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ikeda K, Yamasaki H, Suzuki Y, Hajime Koyama A and Arakawa T: Novel strategy with acidic arginine solution for the treatment of influenza A virus infection (Review) . Exp Ther Med 1: 251-256, 2010.
APA
Ikeda, K., Yamasaki, H., Suzuki, Y., Hajime Koyama, A., & Arakawa, T. (2010). Novel strategy with acidic arginine solution for the treatment of influenza A virus infection (Review) . Experimental and Therapeutic Medicine, 1, 251-256. https://doi.org/10.3892/etm_00000039
MLA
Ikeda, K., Yamasaki, H., Suzuki, Y., Hajime Koyama, A., Arakawa, T."Novel strategy with acidic arginine solution for the treatment of influenza A virus infection (Review) ". Experimental and Therapeutic Medicine 1.2 (2010): 251-256.
Chicago
Ikeda, K., Yamasaki, H., Suzuki, Y., Hajime Koyama, A., Arakawa, T."Novel strategy with acidic arginine solution for the treatment of influenza A virus infection (Review) ". Experimental and Therapeutic Medicine 1, no. 2 (2010): 251-256. https://doi.org/10.3892/etm_00000039